This is the authors' abstract. We don't add key points for this paper.
Integrating clinicopathologic and molecular factors improves the risk assessment of patients with early-stage endometrial carcinoma. Assessment of this integrated risk profile is feasible in daily practice, and holds promise to reduce both overtreatment and undertreatment. Clin Cancer Res; 22(16); 4215-24.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Stelloo et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: